Ep. 204: Exciting Updates from AAAAI 2024
Learn about ground-breaking news and updates from the recent American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting held this February in Washington, D.C. In lay relatable terms, FAACT’s Medical Advisory Board Chair, Dr. Shahzad Mustafa, discusses the approval of Xolair and what it means for the food allergy community. He also shares his thoughts regarding treatments that are on-the-horizon for anaphylaxis from ARS Pharma, Bryn Pharma, Aquestive, DBV Technologies, and Blueprint Medicines.
Resources to keep you in the know:
- New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies (Genentech)
- ARS Pharma
- Bryn Pharma
- Aquestive
- DBV Technologies
- Blueprint Medicines
- Takeda (EOHILIA)
- FAACT's Resources:
You can find FAACT's Roundtable Podcast on Apple Podcast, Pandora, Spotify, Google Podcast, iHeart Radio or wherever you listen to your podcasts.
Follow us on Facebook, Twitter, Instagram, Threads, LinkedIn, Pinterest, TikTok, and YouTube.
Sponsored by: National Peanut Board
Thanks for listening! FAACT invites you to discover more exciting food allergy resources at FoodAllergyAwareness.org!